Onconetix, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $815.4K | $2.5M | $58.5K | — | — |
| Cost of Revenue | — | $182.5K | $1.5M | $1.2M | — | — |
| Gross Profit | — | $632.9K | $1.1M | $-1.1M | — | — |
| Gross Margin | — | 77.6% | 41.8% | -1,927.9% | — | — |
| Operating Expenses | ||||||
| Research & Development | — | — | $154.4K | $1.9M | $4.1M | $1.3M |
| SG&A Expense | — | $7.0M | $11.2M | $14.8M | $9.4M | $2.1M |
| Operating Income | — | $-17.9M | $-56.5M | $-36.0M | $-13.5M | $-3.4M |
| Operating Margin | — | -2,190.0% | -2,238.0% | -61,634.5% | — | — |
| Interest Expense | — | — | — | $671.6K | — | — |
| Pretax Income | — | $-14.0M | $-59.7M | $-37.4M | $-13.4M | — |
| Income Tax Expense | — | $525 | $-1.0M | $-12.6K | $3.16T | $675.73B |
| Net Income | — | $-14.0M | $-58.7M | $-37.4M | $-13.4M | $-3.4M |
| Net Margin | — | -1,721.0% | -2,325.2% | -63,986.5% | — | — |
| EPS (Basic) | — | $-16.56 | $-62.88 | $-3.02 | $-0.04 | $-0.01 |
| EPS (Diluted) | — | $-16.56 | $-62.88 | $-3.02 | $-0.04 | $-0.01 |
| Shares Outstanding (Basic) | 3.6M | 937.7K | 936.7K | 12.4M | 355.9M | 371.2M |
| Shares Outstanding (Diluted) | 3.6M | 937.7K | 936.7K | 12.4M | 355.9M | 371.2M |
| Dividends Per Share | — | — | — | — | $0.04 | — |